MacroGenics, Inc. (NASDAQ:MGNX) Receives Average Recommendation of “Hold” from Brokerages

MacroGenics, Inc. (NASDAQ:MGNX) has received a consensus rating of “Hold” from the eleven analysts that are presently covering the stock, MarketBeat reports. Eight equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $7.63.

A number of brokerages have commented on MGNX. StockNews.com raised shares of MacroGenics from a “sell” rating to a “buy” rating in a research report on Sunday, November 10th. JMP Securities downgraded shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. Evercore ISI raised shares of MacroGenics to a “strong-buy” rating in a research report on Monday, September 16th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 target price on shares of MacroGenics in a research report on Wednesday, November 6th.

Institutional Trading of MacroGenics

Large investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in MacroGenics during the 3rd quarter worth $37,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 4,707 shares during the period. DRW Securities LLC acquired a new stake in shares of MacroGenics in the 2nd quarter worth $56,000. K2 Principal Fund L.P. acquired a new stake in shares of MacroGenics in the 2nd quarter worth $63,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of MacroGenics by 300.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,072 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 12,060 shares during the period. Institutional investors and hedge funds own 96.89% of the company’s stock.

MacroGenics Trading Down 0.3 %

Shares of NASDAQ:MGNX opened at $3.17 on Thursday. MacroGenics has a 52 week low of $2.95 and a 52 week high of $21.88. The company’s 50 day moving average is $3.48 and its two-hundred day moving average is $3.72. The company has a market cap of $198.96 million, a PE ratio of -2.01 and a beta of 2.04.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.